Skip to main content
Erschienen in: Journal of Nephrology 4/2015

01.08.2015 | Original Article

Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells

verfasst von: Gianluigi Zaza, Valentina Masola, Simona Granata, Gloria Bellin, Alessandra Dalla Gassa, Maurizio Onisto, Giovanni Gambaro, Antonio Lupo

Erschienen in: Journal of Nephrology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Prolonged cold ischemia time, the period from the start of perfusion with cold preservation fluid after cessation of circulation due to arterial clamping until transplantation in the recipient, could induce epithelial-to-mesenchymal transition (EMT) in renal tubular cells, a process associated with chronic graft damage. In this context, everolimus (EVE) and sulodexide (SUL) could potentially slow down this process.

Methods

To assess whether SUL (50 μg/ml), EVE (at 5, 10, 100 nM) or their combination were able to inhibit EMT in human renal epithelial proximal tubular cells (HK-2) reoxygenated after 24 h under hypoxic conditions, we used classical biomolecular strategies.

Results

Hypoxia induced upregulation of alpha smooth muscle actin (α-SMA), fibronectin (FN) and vimentin at gene-expression and α-SMA and FN at protein levels. However, the addition, after reoxygenation, of SUL plus low-dose EVE (5 nM) to the cell culture reversed this condition. Moreover, SUL and EVE were able to inhibit the hypoxia-induced Akt phosphorylation in HK2 cells and their morphological changes. Similarly, SUL was able to reverse the hyper-expression of EMT markers induced by high EVE dosage (100 nM) in cells cultured under both normoxic and hypoxic conditions.

Conclusions

Our data reveal, for the first time, that sulodexide, alone or combined to low doses of everolimus, may hinder EMT in renal cells following hypoxia or minimize fibrotic complications due to high dosage of mammalian target of rapamycin inhibitors.
Literatur
1.
Zurück zum Zitat Bon D, Chatauret N, Giraud S, Thuillier R, Favreau F, Hauet T (2012) New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol 8(6):339–347PubMedCrossRef Bon D, Chatauret N, Giraud S, Thuillier R, Favreau F, Hauet T (2012) New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol 8(6):339–347PubMedCrossRef
2.
Zurück zum Zitat Kwiatkowski A, Wszoła M, Kosieradzki M, Danielewicz R, Ostrowski K, Domagala P, Lisik W, Fesołowicz S, Michalak G, Trzebicki J, Durlik M, Paczek L, Rowiński W, Chmura A (2009) The early and long term function and survival of kidney allografts stored before transplantation by hypothermic pulsatile perfusion. A prospective randomized study. Ann Transplant 14:14–17PubMed Kwiatkowski A, Wszoła M, Kosieradzki M, Danielewicz R, Ostrowski K, Domagala P, Lisik W, Fesołowicz S, Michalak G, Trzebicki J, Durlik M, Paczek L, Rowiński W, Chmura A (2009) The early and long term function and survival of kidney allografts stored before transplantation by hypothermic pulsatile perfusion. A prospective randomized study. Ann Transplant 14:14–17PubMed
3.
Zurück zum Zitat Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study Group (2012) Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 366(8):770–771PubMedCrossRef Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study Group (2012) Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 366(8):770–771PubMedCrossRef
4.
Zurück zum Zitat Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML (2006) Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 6:1111–1131PubMedCrossRef Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML (2006) Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 6:1111–1131PubMedCrossRef
5.
Zurück zum Zitat Meier-Kriesche HU, Schold JD, Srinivas TR, Kapplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378–383PubMedCrossRef Meier-Kriesche HU, Schold JD, Srinivas TR, Kapplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378–383PubMedCrossRef
6.
Zurück zum Zitat US Renal Data System, USRDS (2013) Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013 US Renal Data System, USRDS (2013) Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013
7.
Zurück zum Zitat Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82:603–611PubMedCrossRef Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82:603–611PubMedCrossRef
8.
Zurück zum Zitat Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333PubMedCrossRef Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333PubMedCrossRef
9.
Zurück zum Zitat Chapman JR, O’Connell PJ, Nankivell BJ (2005) Chronic renal allograft dysfunction. J Am Soc Nephrol 16(10):3015–3026PubMedCrossRef Chapman JR, O’Connell PJ, Nankivell BJ (2005) Chronic renal allograft dysfunction. J Am Soc Nephrol 16(10):3015–3026PubMedCrossRef
12.
Zurück zum Zitat Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell Tissue Res 347:103–116PubMedCrossRef Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell Tissue Res 347:103–116PubMedCrossRef
13.
Zurück zum Zitat Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF (2005) Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 5:1367–1374PubMedCrossRef Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF (2005) Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 5:1367–1374PubMedCrossRef
14.
Zurück zum Zitat Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, Glotz D, Ancel PY, Rondeau E, Xu-Dubois YC (2006) Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 6:2937–2946PubMedCrossRef Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, Glotz D, Ancel PY, Rondeau E, Xu-Dubois YC (2006) Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 6:2937–2946PubMedCrossRef
15.
Zurück zum Zitat Opelz G, Döhler B (2007) Multicenter analysis of kidney preservation. Transplantation 83:247PubMedCrossRef Opelz G, Döhler B (2007) Multicenter analysis of kidney preservation. Transplantation 83:247PubMedCrossRef
16.
Zurück zum Zitat Hernández D, Estupiñán S, Pérez G, Rufino M, González-Posada JM, Luis D, Delgado P, Rodríguez A, Marrero D, Porrini E, Torres A (2008) Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transplant Int 21(10):955–962CrossRef Hernández D, Estupiñán S, Pérez G, Rufino M, González-Posada JM, Luis D, Delgado P, Rodríguez A, Marrero D, Porrini E, Torres A (2008) Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transplant Int 21(10):955–962CrossRef
17.
Zurück zum Zitat Salahudeen AK, Haider N, May W (2004) Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 65(2):713–718PubMedCrossRef Salahudeen AK, Haider N, May W (2004) Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 65(2):713–718PubMedCrossRef
18.
19.
Zurück zum Zitat Pontrelli P, Rossini M, Infante B et al (2008) Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85:125–134PubMedCrossRef Pontrelli P, Rossini M, Infante B et al (2008) Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85:125–134PubMedCrossRef
20.
Zurück zum Zitat Geissler EK, Schlitt HJ (2010) The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 78(11):1075–1079PubMedCrossRef Geissler EK, Schlitt HJ (2010) The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 78(11):1075–1079PubMedCrossRef
21.
Zurück zum Zitat Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One 7(3):e33626PubMedCentralPubMedCrossRef Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One 7(3):e33626PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10:213PubMedCentralPubMedCrossRef Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10:213PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Masola V, Zaza G, Gambaro G (2014) Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1):i74–i79PubMedCrossRef Masola V, Zaza G, Gambaro G (2014) Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1):i74–i79PubMedCrossRef
24.
Zurück zum Zitat Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A (2013) Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 11:292PubMedCentralPubMedCrossRef Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A (2013) Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 11:292PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Kosieradzki M, Rowiński W (2008) Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 40(10):3279–3288PubMedCrossRef Kosieradzki M, Rowiński W (2008) Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 40(10):3279–3288PubMedCrossRef
26.
Zurück zum Zitat van der Vliet JA, Warlé MC (2013) The need to reduce cold ischemia time in kidney transplantation. Curr Opin Organ Transplant 18(2):174–178PubMedCrossRef van der Vliet JA, Warlé MC (2013) The need to reduce cold ischemia time in kidney transplantation. Curr Opin Organ Transplant 18(2):174–178PubMedCrossRef
27.
Zurück zum Zitat Ponticelli C (2014) Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 29(6):1134–1140PubMedCrossRef Ponticelli C (2014) Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 29(6):1134–1140PubMedCrossRef
28.
Zurück zum Zitat Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503–1520PubMedCrossRef Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503–1520PubMedCrossRef
29.
Zurück zum Zitat Perico N, Cattaneo D, Sayegh MH, Remuzzi G (2004) Delayed graft function in kidney transplantation. Lancet 364(9447):1814–1827PubMedCrossRef Perico N, Cattaneo D, Sayegh MH, Remuzzi G (2004) Delayed graft function in kidney transplantation. Lancet 364(9447):1814–1827PubMedCrossRef
30.
Zurück zum Zitat Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M (2004) Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65:871–880PubMedCrossRef Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M (2004) Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65:871–880PubMedCrossRef
31.
Zurück zum Zitat Gottmann U, Mueller-Falcke A, Schnuelle P, Birck R, Nickeleit V, van der Woude FJ, Yard BA, Braun C (2007) Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys. Transpl Int 20(6):542–549PubMedCrossRef Gottmann U, Mueller-Falcke A, Schnuelle P, Birck R, Nickeleit V, van der Woude FJ, Yard BA, Braun C (2007) Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys. Transpl Int 20(6):542–549PubMedCrossRef
32.
Zurück zum Zitat Gedik HS, Korkmaz K, Erdem H, Karakilic E, Lafci G, Ankarali H (2012) Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg 7:123PubMedCentralPubMedCrossRef Gedik HS, Korkmaz K, Erdem H, Karakilic E, Lafci G, Ankarali H (2012) Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg 7:123PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Zhou T, Chen JL, Song W, Wang F, Zhang MJ, Ni PH, Geng JG (2002) Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats. World J Gastroenterol 8(5):897–900PubMed Zhou T, Chen JL, Song W, Wang F, Zhang MJ, Ni PH, Geng JG (2002) Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats. World J Gastroenterol 8(5):897–900PubMed
34.
Zurück zum Zitat Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group, Sirolimus CONVERT Trial Study Group (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233PubMedCrossRef Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group, Sirolimus CONVERT Trial Study Group (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233PubMedCrossRef
35.
Zurück zum Zitat Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K (2008) Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 22:366PubMedCrossRef Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K (2008) Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 22:366PubMedCrossRef
36.
Zurück zum Zitat Budde K, Becker T, Sommerer C et al (2009) Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus study. Am J Transplant 9:259 (Abstract 237) Budde K, Becker T, Sommerer C et al (2009) Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus study. Am J Transplant 9:259 (Abstract 237)
37.
Zurück zum Zitat Weir M, Mulgaonkar S, Pearson T et al (2009) Mycophenolatemofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 9:200 (Abstract 33) Weir M, Mulgaonkar S, Pearson T et al (2009) Mycophenolatemofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 9:200 (Abstract 33)
38.
Zurück zum Zitat Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115PubMedCrossRef Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115PubMedCrossRef
39.
Zurück zum Zitat Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768):837–847PubMedCrossRef Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768):837–847PubMedCrossRef
40.
Zurück zum Zitat Hong JC, Kahan BD (2001) A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71(9):1320–1328PubMedCrossRef Hong JC, Kahan BD (2001) A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71(9):1320–1328PubMedCrossRef
41.
Zurück zum Zitat Pallet N, Legendre C (2013) Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 12(2):177–186PubMedCrossRef Pallet N, Legendre C (2013) Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 12(2):177–186PubMedCrossRef
42.
Zurück zum Zitat Lieberthal W, Fuhro R, Andry CC (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693–F706PubMed Lieberthal W, Fuhro R, Andry CC (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693–F706PubMed
43.
Zurück zum Zitat Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC (2009) Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 22:681–687PubMedCrossRef Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC (2009) Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 22:681–687PubMedCrossRef
44.
Zurück zum Zitat Dantal J, Berthoux F, Moal MC (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-months results of a randomized, multicenter trial. Transpl Int 23(11):1084–1093PubMedCrossRef Dantal J, Berthoux F, Moal MC (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-months results of a randomized, multicenter trial. Transpl Int 23(11):1084–1093PubMedCrossRef
45.
Zurück zum Zitat Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:403280PubMedCentralPubMedCrossRef Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:403280PubMedCentralPubMedCrossRef
46.
Zurück zum Zitat Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A (2014) mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol 5:495CrossRef Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A (2014) mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol 5:495CrossRef
47.
Zurück zum Zitat Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8(4):742–753PubMedCentralPubMedCrossRef Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8(4):742–753PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940PubMedCrossRef Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940PubMedCrossRef
50.
Zurück zum Zitat Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856–5864PubMedCrossRef Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856–5864PubMedCrossRef
51.
Zurück zum Zitat Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10):2658–2664PubMed Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10):2658–2664PubMed
Metadaten
Titel
Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells
verfasst von
Gianluigi Zaza
Valentina Masola
Simona Granata
Gloria Bellin
Alessandra Dalla Gassa
Maurizio Onisto
Giovanni Gambaro
Antonio Lupo
Publikationsdatum
01.08.2015
Verlag
Springer International Publishing
Erschienen in
Journal of Nephrology / Ausgabe 4/2015
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-015-0216-y

Weitere Artikel der Ausgabe 4/2015

Journal of Nephrology 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.